# About Telehealth Retatrutide — Independent Research Digest

> Telehealth Retatrutide is an independent editorial publisher summarizing Phase 1-3 trial evidence on retatrutide (LY3437943). Not a clinic. Not a vendor. Not a prescription service.

Independent editorial. No clinical services.

## The publisher

Telehealth Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed and clinical-trial research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name is an exact-match domain — a digital publishing convention tied to the search terms people use when looking for information about this compound. The word "telehealth" in our name is editorial framing, not a description of services offered. There are no telehealth consultations here, no prescriptions filled, no clinical staff, and no patient-provider relationship of any kind.

## What we track

This site focuses on the cardiometabolic evidence thread in retatrutide's clinical development: weight, glycemia, liver fat, blood pressure, lipids, and the ongoing cardiovascular and kidney outcome trials. That lens was chosen because the Phase 2 findings in those domains are among the most clinically significant in the incretin-class literature to date — and because the Phase 3 program will ultimately answer whether those metabolic signals translate to reduced cardiovascular and kidney events.

We summarize published findings from Phase 1b through Phase 3, structural biology, meta-analyses, and the most recent 2024-2026 studies. Every quantitative claim on this site is cited to a numbered reference. When the evidence is uncertain or incomplete, we say so.

We track the evidence as it moves from Phase 2 toward potential regulatory review. That is the tagline and the mission: measured optimism grounded in what the data actually show.

## What we are not

We are not affiliated with Eli Lilly or any pharmaceutical company. We have no financial relationship with any vendor, clinical trial, compound supplier, or healthcare provider. We have not received funding from any party with a commercial interest in retatrutide.

We do not have doctors, pharmacists, or clinical staff. We do not advise on whether to use retatrutide. We do not provide sourcing guidance. We do not link to suppliers. Any language on this site that describes reported effects or community signals is editorial commentary on what people have reported in public forums — it is not a recommendation, endorsement, or clinical finding.

Retatrutide is investigational. No reader of this site should interpret anything here as an instruction, a suggestion, or a basis for a personal decision about their own health. Those decisions belong to you and, where relevant, a licensed healthcare provider with knowledge of your individual situation.

## Contact and corrections

We take accuracy seriously. If you find a citation error, a factual misstatement, or a claim that appears to exceed what the cited study actually found, please use the [contact page](/contact) to reach us. We will review and correct promptly. The [Retatrutide references](/references) page lists every source we use; all are publicly accessible.

---

An instrument readout of the Phase 1–3 retatrutide trial record — cardiometabolic endpoints logged to primary source, gaps noted in plain view, and no clinic, prescription, or product behind the screen.